Literature DB >> 18469525

Cancerous miRNAs and their regulation.

Xu-Bao Shi1, Clifford G Tepper, Ralph W deVere White.   

Abstract

Although they account for only a very minor fraction of the expressed genome, microRNAs (miRNAs) are pivotal regulators of development and cellular homeostasis through their control of diverse cellular processes including proliferation, differentiation, apoptosis, survival, motility and morphogenesis. Accordingly, several miRNAs have been functionally classified as proto-oncogenes or tumor suppressors and are aberrantly expressed in different cancer types. Deregulation (e.g., overexpression or loss of expression) of these so-called "cancerous" miRNAs can figure prominently in tumor initiation and progression by elaborating an inappropriate cellular program promoting uncontrolled proliferation, favoring survival, inhibiting differentiation and/or promoting invasive behavior. These features would certainly promote tumor dissemination and persistence by favoring metastasis and therapy resistance. Cancerous miRNAs therefore represent attractive molecules for exploitation as biomarkers and therapeutic targets. In this review, we highlight recently characterized cancerous miRNAs and the mechanisms through which they contribute to the pathogenesis of human cancers. We also discuss the signal transduction pathways that regulate the expression of these miRNAs with particular attention to several essential transcription factors such as Myc, p53 and the androgen receptor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18469525     DOI: 10.4161/cc.7.11.5977

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  45 in total

1.  miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis.

Authors:  Kevin Beezhold; Jia Liu; Hong Kan; Terry Meighan; Vince Castranova; Xianglin Shi; Fei Chen
Journal:  Toxicol Sci       Date:  2011-07-12       Impact factor: 4.849

2.  Interrelation of androgen receptor and miR-30a and miR-30a function in ER-, PR-, AR+ MDA-MB-453 breast cancer cells.

Authors:  Shuhua Lyu; Han Liu; Xia Liu; Shan Liu; Yahong Wang; Qi Yu; Yun Niu
Journal:  Oncol Lett       Date:  2017-08-21       Impact factor: 2.967

Review 3.  Epigenomics, gestational programming and risk of metabolic syndrome.

Authors:  M Desai; J K Jellyman; M G Ross
Journal:  Int J Obes (Lond)       Date:  2015-02-02       Impact factor: 5.095

Review 4.  Restoring TGFβ1 pathway-related microRNAs: possible impact in metastatic prostate cancer development.

Authors:  Juliana Inês Santos; Ana Luísa Teixeira; Francisca Dias; Mónica Gomes; Augusto Nogueira; Joana Assis; Rui Medeiros
Journal:  Tumour Biol       Date:  2014-04-25

5.  Low expression of microRNA-30c promotes prostate cancer cells invasion involved in downregulation of KRAS protein.

Authors:  Jun Zhang; Xilong Wang; Yangyun Wang; Ruixian Peng; Zhiyuan Lin; Yang Wang; Bo Hu; Jifeng Wang; Guowei Shi
Journal:  Oncol Lett       Date:  2017-05-12       Impact factor: 2.967

6.  miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.

Authors:  Nicola Amodio; Dina Bellizzi; Marzia Leotta; Lavinia Raimondi; Lavinia Biamonte; Patrizia D'Aquila; Maria Teresa Di Martino; Teresa Calimeri; Marco Rossi; Marta Lionetti; Emanuela Leone; Giuseppe Passarino; Antonino Neri; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Cell Cycle       Date:  2013-09-25       Impact factor: 4.534

Review 7.  The role of microRNA in castration-resistant prostate cancer.

Authors:  William Thieu; Derya Tilki; Ralph de Vere White; Christopher P Evans
Journal:  Urol Oncol       Date:  2014-07       Impact factor: 3.498

Review 8.  Study of apoptosis-related interactions in colorectal cancer.

Authors:  Himanshu Arora; Rehana Qureshi; M A Rizvi; Sharad Shrivastava; Mordhwaj S Parihar
Journal:  Tumour Biol       Date:  2016-09-15

9.  miRNA-Based Therapeutic Strategies.

Authors:  Masaharu Ishida; Florin M Selaru
Journal:  Curr Anesthesiol Rep       Date:  2012-12-24

10.  MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor.

Authors:  Jun Tie; Yanglin Pan; Lina Zhao; Kaichun Wu; Jie Liu; Shiren Sun; Xuegang Guo; Biaoluo Wang; Yi Gang; Yongguo Zhang; Quanjiang Li; Taidong Qiao; Qingchuan Zhao; Yongzhan Nie; Daiming Fan
Journal:  PLoS Genet       Date:  2010-03-12       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.